Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations

被引:0
作者
Lu Wang
Yong Duan
Pieter Stouten
George V. De Lucca
Ronald M. Klabe
Peter A. Kollman
机构
[1] University of California,Department of Pharmaceutical Chemistry
[2] DuPont Pharmaceutical Company,DuPont Experimental Station E500
来源
Journal of Computer-Aided Molecular Design | 2001年 / 15卷
关键词
continuum electrostatics; cyclic urea inhibitor; DMP323; free energy perturbation; HIV-1 protease; hydroxyl group; pKa;
D O I
暂无
中图分类号
学科分类号
摘要
The cyclic urea inhibitors of HIV-1 protease generally have two hydroxyl groups on the seven-membered ring. In this study, free energy perturbation and continuum electrostatic calculations were used to study the contributions of the two hydroxyl groups to the binding affinity and solubility of a cyclic urea inhibitor DMP323. The results indicated that the inhibitor with one hydroxyl group has better binding affinity and solubility than the inhibitor with two hydroxyl groups. Therefore, removal of one hydroxyl group from DMP323 may help to improve the properties of DMP323. This is also likely to be true for other cyclic urea inhibitors. The study also illustrated the difficulty in accurate modeling of the binding affinities of HIV-1 protease inhibitors, which involves many possible protonation states of the two catalytic aspartic acids in the active site of the enzyme.
引用
收藏
页码:145 / 156
页数:11
相关论文
共 184 条
[1]  
Debouck C.(1992)undefined AIDS Res. Human Retroviruses 8 153-341
[2]  
Katz R.A.(1994)undefined Ann. Rev. Biochem. 63 133-391
[3]  
Skalka M.(1993)undefined Science 260 1273-undefined
[4]  
Weiss R.A.(1993)undefined Science 260 1286-undefined
[5]  
Johnston M.I.(1987)undefined Proc. Natl. Acad. Sci. 84 7009-undefined
[6]  
Hoth D.E.(1989)undefined Science 245 616-undefined
[7]  
Suguna K.(1998)undefined Ann. Rev. Biophys. Biomol. Struct. 27 249-undefined
[8]  
Padlan E.A.(1994)undefined Annu. Rep. Med. Chem. 29 133-undefined
[9]  
Smith C.W.(1995)undefined Ann. Rep. Med. Chem. 30 139-undefined
[10]  
Carlson W.D.(1997)undefined Pharm. World Sci. 19 159-undefined